HomeDiscoveryPubblicazioniPubblicazioni 2009

Pubblicazioni 2009




Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Brasca MG, Amboldi A, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D’Alessio R, Fioentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, et al.
J. Med. Chem.
(2009) 52, 5152-5163

A submarine journey: the pyrrole-imidazole alkaloids
Forte B, Malgesini B, Piutti C, Quartieri F, Scolaro A, Papeo GL
Marine Drugs
(2009) 7, 705-753

In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma
Pellizzari Tregno F, Sau A, Pezzola S, Geroni C, Lapenta C, Spada M, Filomeni G, Bonanno E, Federici G, Caccuri AM
Eur J of Cancer
(2009) 45, 2606-2617

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach
Rocchetti M, DelBene F, Germani M, Fiorentini F, Poggeti I, Pesenti E, Magni P, DeNicolao G
Eur J of Cancer
(2009) 45, 3336-3346

A Perl procedure for protein identification by peptide mass fingerprinting
Tiengo A, Barbarini N, Troiani S, Rusconi L, Magni P
BMC Bioinformatics
(2009) 10 (suppl 12) S11

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a Xenograft mouse model
Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf T.
(2009) 11(9), 934-944

Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia.
Radaelli E , Marchesi F, Patton V, Scanziani E
Vet Pathol.
(2009) 46(6):1301-5

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, Moll J, Burris HA.
Clin Cancer Res.
(2009) 15(21):6694-701

Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays.
Gasparri F, Wang N, Skog S, Galvani A, Eriksson S.
Eur J Cell Biol.
(2009) 88(12):779-85

Poly(ADP-ribose) polymerase ibhibition in cancer therapy: Are we close to maturity?
Papeo GL, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A, Montagnoli A
Expert Opinion Therapeutic Patents
(2009) 19(10), 1377-1400

Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)
Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A, Vaccaro W, Poss M, Trainor G, Lorenzi M, Gottardis M, Jayaraman L, Purandare A
Bioorganic & Medicinal Chemistry Letters
(2009) 9(11), 2924-2927

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients with Advanced or Metastatic Solid Tumors
Steeghs N, Eskens FALM, Gelderblom H, Verweij J, Nortier JWR, Ouwerkerk J, Noort C , Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge M.
Journal Clinical Oncology
(2009) 27(30), 5094-5101

Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships
Ermoli A, Bargiotti A, Brasca MG, Ciavolella A, Colombo N, Fachin G, Isacchi A, Menichincheri M, Molinari A, Montagnoli A, Pillan A, Rainoldi S, Sirtori FR, Sola F, Thieffine S, Tibolla M, Valsasina B, Volpi D, Santocanale C, Vanotti E
Journal of Medicinal Chemistry
(2009) 52(14), 4380-4390

First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Menichincheri M et al.
Chem Med Chem
(2009) 52(2), 293-307

Design, synthesis, and biological evaluation of levoglucosenone-derived ras activation inhibitors
Müller C, Gomez-Zurita Frau MA, Ballinari D, Colombo S, Bitto A, Martegani E, Airoldi C, van Neuren AS, Stein M, Weiser J, Battistini C, Peri
Chem Med Chem
(2009) (4), 524-528

Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease
Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E, Alzani R
Histology and Histopathology
(2009) 24(7), 879-891

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A.
(2009) 30(7), 1073-1081

A straightforward total synthesis of (-)-chaetominine
Malgesini B, Forte B, Borghi D, Quartieri F, Papeo G, Gennari C
Chemistry: a European Journal
(2009) 15(32), 7922-7929

Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P, Moll J
Curr Opin Drug Discov Devel
(2009) 12(4), 533-542

Highly efficient synthesis of 5-benzyl substituted 3-aminoindazoles
Orsini P, Menichincheri M, Vanotti E, Panzeri A
Tetrahedron letters
(2009) 50, 3098-3100

First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Finding
Menichincheri M, Bargiotti A, Bossi R, Cirla A, D’Alessio R, Forte B, Martina K, Orsini P, Orzi F, Pillan A, Scolaro A, Tibolla M, Varasi M, Vanotti E et al.
Journal of Medicinal Chemistry
(2009) 52 (2), 293-307

Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target
Farace P, D’Ambrosio D, Merigo F, Galliè M, Nanni C, Spinelli A, Fanti S, Degrassi A, Sbarbati A, Rubello D, Marzola P
Eur J Nucl Med Mol Imaging
(2009) 36(4), 616-623

Stereoselective Synthesis of (Z)-Axino- and (Z)-Debromoaxinohydantoin
Tutino F, Posteri H, Borghi D, Quartieri F, Mongelli N, Papeo G
(2009) 65, 2372-2376

Improved Synthesis of Polyfluorinated L-lysine for 19F NMR-Based Screening
Malgesini B, Felder E, Mongelli N, Papeo G
Mol. Divers
(2009) 13, 53-56

Estrogen Suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
Jannuzzo MG, DiSalle E, Spinelli R, Pirotta N, Buchan P, Bello A
Breast Cancer Res Treat
(2009) 113(3), 491-499